Quantcast

Latest National Institute of Allergy and Infectious Diseases Stories

2014-09-15 23:07:02

BioFactura, Inc. is a collaborator on a grant awarded to the Geneva Foundation. Eboladrug development funding will be provided under a Partnerships for Biodefense grant from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID). Frederick, MD (PRWEB) September 15, 2014 BioFactura, Inc. is a collaborator on a grant awarded to the Geneva Foundation. Ebola drug development funding will be provided under a Partnerships for Biodefense grant from...

2014-09-09 08:30:50

New patent includes composition of matter claims PRINCETON, N.J., Sept. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the US Patent and Trademark Office (US PTO) granted patent 8,808,710 entitled "Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine...

2014-09-08 08:29:28

Presentation to be Webcast Live, 1:15 PM EDT, September 9th PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16(th) Annual Rodman & Renshaw Global...

2014-08-28 12:29:44

Unprecedented international consortium -- including the University of Maryland School of Medicine and NIH -- now assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine BALTIMORE and LONDON, Aug. 28, 2014 /PRNewswire/ -- A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of an series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400...

2014-08-11 08:28:46

PRINCETON, N.J., Aug. 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the second quarter and six months ended June 30, 2014. Soligenix's revenues for the quarter and six months ended June 30,...

2014-08-01 08:26:07

Awarded $2.1 million in additional funding PRINCETON, N.J., Aug. 1, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to...

2014-07-24 12:27:52

MENLO PARK, Calif., July 24, 2014 /PRNewswire/ -- SRI International has been awarded a new $49 million, seven-year contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to conduct preclinical development of potential therapies for HIV infection and AIDS. The contract supports the development of drugs to treat HIV and AIDS and the complications and opportunistic infections associated with the disease, as well as...

Child Believed To Be Cured Of HIV Now Has Detectable Virus Levels
2014-07-11 07:38:26

redOrbit Staff & Wire Reports - Your Universe Online The Mississippi infant believed to have been cured of HIV following an extended remission now once again has “detectable levels” of the AIDS-causing virus in her blood, the US National Institute of Allergy and Infectious Diseases (NIAID) has confirmed. The child was born prematurely in 2010 to an HIV-infected mother who had not been diagnosed until the time of delivery and had not been given antiretroviral medication during...

2014-07-07 12:29:07

Prestigious Biomedical Researcher and Author Joins Innovator in DNA Capture Technology SAN DIEGO, July 7, 2014 /PRNewswire/ -- Diomics, an innovator in DNA capture technology, today announced the appointment of Thomas Kindt, Ph.D., as Diomic's chief scientific officer (CSO) effective July 7, 2014. Dr. Kindt brings more than 30 years of relevant industry experience to his new role having previously served as Director of Intramural Research of the National Institute of Allergy and...

2014-07-01 08:30:44

SAN DIEGO, July 1, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB(®) library and proprietary antibody conjugation technology platforms have...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'